Top-Rated StocksTop-RatedNASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free CRNX Stock Alerts $48.87 +0.94 (+1.96%) (As of 11:23 AM ET) Add Compare Share Share Today's Range$48.41▼$49.6450-Day Range$37.93▼$50.8952-Week Range$15.76▼$51.29Volume121,231 shsAverage Volume779,545 shsMarket Capitalization$3.85 billionP/E RatioN/ADividend YieldN/APrice Target$58.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Crinetics Pharmaceuticals alerts: Email Address Crinetics Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside21.9% Upside$58.42 Price TargetShort InterestHealthy6.23% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.17Based on 29 Articles This WeekInsider TradingSelling Shares$13.82 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.34) to ($3.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.81 out of 5 starsMedical Sector657th out of 2,771 stocksPharmaceutical Preparations Industry275th out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCrinetics Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Crinetics Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.23% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently decreased by 5.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 1.8 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Crinetics Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,817,328.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crinetics Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.34) to ($3.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -12.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -12.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crinetics Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyGuard Against the Coming Financial UpheavalAmerica’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More CRNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Stock News HeadlinesMay 12 at 4:25 AM | insidertrades.comRichard Scott Struthers Sells 107,448 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockApril 18, 2024 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 14,375 Shares of StockMay 14 at 10:33 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Wave Life Sciences (WVE) and Intellia Therapeutics (NTLA)May 13 at 7:31 PM | finance.yahoo.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call TranscriptMay 13 at 7:00 AM | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Earns "Market Outperform" Rating from JMP SecuritiesMay 13 at 6:13 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)May 11 at 12:45 PM | finance.yahoo.comInvestors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three yearsMay 11 at 7:45 AM | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | markets.businessinsider.comBuy Rating for Crinetics Pharmaceuticals: Strong Financials and Promising Clinical DataMay 10, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial ResultsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals on Strong Drug Pipeline and Market PotentialMay 10, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | investorplace.comCRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 52-Week High on Analyst UpgradeMay 8, 2024 | markets.businessinsider.comPromising Outlook for Crinetics Pharmaceuticals Ahead of CRN04894 Phase 2 Data ReleaseMay 8, 2024 | finance.yahoo.comCrinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024May 8, 2024 | americanbankingnews.comCrinetics Pharmaceuticals (CRNX) to Release Quarterly Earnings on ThursdayMay 8, 2024 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Increased to $97.00 by Analysts at Piper SandlerMay 2, 2024 | globenewswire.comCrinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024April 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | investing.comCrinetics Pharmaceuticals COO sells shares worth over $1.4 millionSee More Headlines Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Stock Price Target$58.42 High Stock Price Target$97.00 Low Stock Price Target$35.00 Potential Upside/Downside+21.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,530,000.00 Net Margins-4,223.27% Pretax Margin-11,641.14% Return on Equity-42.50% Return on Assets-36.96% Debt Debt-to-Equity RatioN/A Current Ratio17.72 Quick Ratio17.72 Sales & Book Value Annual Sales$4.01 million Price / Sales942.58 Cash FlowN/A Price / Cash FlowN/A Book Value$8.07 per share Price / Book5.94Miscellaneous Outstanding Shares78,860,000Free Float73,340,000Market Cap$3.78 billion OptionableOptionable Beta0.63 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 62)Founder, President, CEO & Director Comp: $870.69kDr. Stephen F. Betz Ph.D. (Age 58)Founder & Chief Scientific Officer Comp: $618.58kMr. Marc J. C. Wilson (Age 45)Chief Financial Officer Comp: $585.54kMr. James Hassard (Age 58)Chief Commercial Officer Comp: $513.34kDr. Dana Pizzuti M.D. (Age 68)Chief Development Officer Comp: $493.62kMr. Jeff E. Knight (Age 53)Chief Operating Officer Comp: $237.64kMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerDr. Alan S. Krasner M.D. (Age 61)Chief Medical Officer Comp: $571.97kMr. Kevin CappsHead of Intellectual PropertyMore ExecutivesKey CompetitorsSummit TherapeuticsNASDAQ:SMMTBiohavenNYSE:BHVNAxsome TherapeuticsNASDAQ:AXSMInsmedNASDAQ:INSMUltragenyx PharmaceuticalNASDAQ:RAREView All CompetitorsInsiders & InstitutionsStemPoint Capital LPBought 175,000 shares on 5/14/2024Ownership: 0.000%Decheng Capital LLCBought 157,958 shares on 5/14/2024Ownership: 0.200%Seven Eight Capital LPSold 14,402 shares on 5/13/2024Ownership: 0.026%Vanguard Group Inc.Bought 72,624 shares on 5/10/2024Ownership: 4.540%Lord Abbett & CO. LLCBought 187,280 shares on 5/9/2024Ownership: 1.225%View All Insider TransactionsView All Institutional Transactions CRNX Stock Analysis - Frequently Asked Questions Should I buy or sell Crinetics Pharmaceuticals stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks. What is Crinetics Pharmaceuticals' stock price target for 2024? 12 equities research analysts have issued 12-month price objectives for Crinetics Pharmaceuticals' shares. Their CRNX share price targets range from $35.00 to $97.00. On average, they anticipate the company's stock price to reach $58.42 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts. How have CRNX shares performed in 2024? Crinetics Pharmaceuticals' stock was trading at $35.58 at the beginning of 2024. Since then, CRNX stock has increased by 34.7% and is now trading at $47.93. View the best growth stocks for 2024 here. When is Crinetics Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CRNX earnings forecast. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its earnings results on Thursday, May, 9th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.09. The business had revenue of $0.64 million for the quarter, compared to analysts' expectations of $0.20 million. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 42.50% and a negative net margin of 4,223.27%. The company's quarterly revenue was down 76.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.85) earnings per share. What ETFs hold Crinetics Pharmaceuticals' stock? ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), BNY Mellon Innovators ETF (BKIV) and First Trust BuyWrite Income ETF (FTHI). What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC). When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.54%), Jennison Associates LLC (3.58%), Lord Abbett & CO. LLC (1.23%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.69%), StemPoint Capital LP (0.00%) and Decheng Capital LLC (0.20%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey and Stephen F Betz. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRNX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.